致编辑的信：回应评论文章《甲状旁腺激素与抗吸收药物的联合应用：相加效应还是双能X线吸收仪的修饰作用》 - Suppr | 超能文献

Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.

作者信息

Leder Benjamin Z, Tsai Joy N, Burnett-Bowie Sherri-Anne, Bouxsein Mary L, Neer Robert M

机构信息

Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

Department of Medicine, Endocrine Unit, Massachusetts General Hospital, Boston, MA, United States.

出版信息

Bone. 2016 Aug;89:73-74. doi: 10.1016/j.bone.2016.04.026. Epub 2016 May 5.

DOI:10.1016/j.bone.2016.04.026

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Letter to the editor in response to the commentary, "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.致编辑的信：回应评论文章《甲状旁腺激素与抗吸收药物的联合应用：相加效应还是双能X线吸收仪的修饰作用》

Bone. 2016 Aug;89:73-74. doi: 10.1016/j.bone.2016.04.026. Epub 2016 May 5.

2

Response to letter to the editor by Leder et al. regarding commentary "Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics".

Bone. 2016 Aug;89:75-76. doi: 10.1016/j.bone.2016.04.027. Epub 2016 Apr 30.

3

Commentary: Concurrent administration of PTH and antiresorptives: Additive effects or DXA cosmetics.评论：甲状旁腺激素（PTH）与抗吸收药物的联合使用：相加效应还是双能X线吸收测定法的修饰作用。

Bone. 2016 May;86:139-42. doi: 10.1016/j.bone.2016.02.009. Epub 2016 Mar 2.

4

Letter to the Editor: Combination Treatment With Teriparatide and Denosumab in Osteoporosis.致编辑的信：特立帕肽与地诺单抗联合治疗骨质疏松症

J Clin Endocrinol Metab. 2016 Aug;101(8):L80-1. doi: 10.1210/jc.2016-2343.

5

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.地诺单抗与特立帕肽在绝经后骨质疏松症中的转换（DATA-Switch研究）：一项随机对照试验的扩展

Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2.

6

Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.在DATA（地诺单抗与特立帕肽给药）研究随机对照试验中，绝经后女性接受特立帕肽、地诺单抗或两者联合治疗的疗效。

J Clin Densitom. 2016 Jul-Sep;19(3):346-51. doi: 10.1016/j.jocd.2016.01.004. Epub 2016 Feb 15.

7

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.特立帕肽与地诺单抗对完整甲状旁腺激素及骨形成指标的不同影响：AVA骨质疏松症研究

J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.

8

The role of teriparatide in sequential and combination therapy of osteoporosis.特立帕肽在骨质疏松症序贯及联合治疗中的作用。

Swiss Med Wkly. 2014 Jun 4;144:w13952. doi: 10.4414/smw.2014.13952. eCollection 2014.

9

[Combination or sequential treatment using PTH and anti-resorption therapies].

Clin Calcium. 2012 Mar;22(3):415-20.

10

Reply to Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use".

J Clin Endocrinol Metab. 2020 May 1;105(5). doi: 10.1210/clinem/dgz123.

引用本文的文献

1

The Notch pathway regulates the bone gain induced by PTH anabolic signaling.Notch 通路调节 PTH 合成代谢信号诱导的骨量增加。

FASEB J. 2022 Mar;36(3):e22196. doi: 10.1096/fj.202101807R.

2

MMP14 is a novel target of PTH signaling in osteocytes that controls resorption by regulating soluble RANKL production.MMP14 是破骨细胞中 PTH 信号的一个新靶点，通过调节可溶性 RANKL 的产生来控制吸收。

FASEB J. 2018 May;32(5):2878-2890. doi: 10.1096/fj.201700919RRR. Epub 2018 Jan 17.